Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries

Yock Young Dan, John B. Wong, Saeed S. Hamid, KwangHyub Han, Ji Dong Jia, Chun Jen Liu, Teerha Piratvisuth, Anna S.F. Lok, Seng Gee Lim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. Methods: The working party consisted of expert hepatologists, virologists and epidemiologists from 11 representative countries in the Asia Pacific region. Meetings were conducted at the 20th APASL Annual Meeting in 2010 to determine consensus estimates for modeling and at the 21st and 22nd APASL meetings in 2011 and 2012, respectively to review and approve the models. Results: The consensus cost-effectiveness model used Singapore as base case analysis and was validated using actual data from the Singapore Cancer, Diseases and Death Registries. Simulation for Singapore, China, Thailand, Pakistan, Taiwan and Korea were performed. Antivirals with high resistance barriers like entecavir and tenofovir had the highest retail cost but were the most cost-effective therapy in developed countries such as Singapore, Taiwan and Korea while generic tenofovir was most cost effective in Thailand and Pakistan. The cost effectiveness of different treatment strategies varied significantly between countries and was affected by medication cost, economic affordability, access to liver transplantation and the prevailing health of the general population. Conclusion: Choosing treatment strategies for hepatitis B based on low retail drug cost can be misleading because more expensive drugs may be more cost effective when considering long-term health outcomes and costs. Cost-effectiveness data should be individualized to countries based on their unique socio-economic conditions. Governmental policies which subsidize more costly drugs that have lower risk of drug resistance can benefit more patients.

Original languageEnglish
Pages (from-to)382-394
Number of pages13
JournalHepatology International
Volume8
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Chronic Hepatitis B
Tenofovir
Cost-Benefit Analysis
Singapore
Costs and Cost Analysis
Pakistan
Thailand
Korea
Hepatitis B
Taiwan
Liver
Economics
Therapeutics
Drug Costs
Developed Countries
Drug Resistance
Pharmaceutical Preparations
Health Care Costs
Liver Transplantation
Antiviral Agents

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Dan, Yock Young ; Wong, John B. ; Hamid, Saeed S. ; Han, KwangHyub ; Jia, Ji Dong ; Liu, Chun Jen ; Piratvisuth, Teerha ; Lok, Anna S.F. ; Lim, Seng Gee. / Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. In: Hepatology International. 2014 ; Vol. 8, No. 3. pp. 382-394.
@article{048fb03d68cf48b79f74ed018fb1fc97,
title = "Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries",
abstract = "Purpose: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. Methods: The working party consisted of expert hepatologists, virologists and epidemiologists from 11 representative countries in the Asia Pacific region. Meetings were conducted at the 20th APASL Annual Meeting in 2010 to determine consensus estimates for modeling and at the 21st and 22nd APASL meetings in 2011 and 2012, respectively to review and approve the models. Results: The consensus cost-effectiveness model used Singapore as base case analysis and was validated using actual data from the Singapore Cancer, Diseases and Death Registries. Simulation for Singapore, China, Thailand, Pakistan, Taiwan and Korea were performed. Antivirals with high resistance barriers like entecavir and tenofovir had the highest retail cost but were the most cost-effective therapy in developed countries such as Singapore, Taiwan and Korea while generic tenofovir was most cost effective in Thailand and Pakistan. The cost effectiveness of different treatment strategies varied significantly between countries and was affected by medication cost, economic affordability, access to liver transplantation and the prevailing health of the general population. Conclusion: Choosing treatment strategies for hepatitis B based on low retail drug cost can be misleading because more expensive drugs may be more cost effective when considering long-term health outcomes and costs. Cost-effectiveness data should be individualized to countries based on their unique socio-economic conditions. Governmental policies which subsidize more costly drugs that have lower risk of drug resistance can benefit more patients.",
author = "Dan, {Yock Young} and Wong, {John B.} and Hamid, {Saeed S.} and KwangHyub Han and Jia, {Ji Dong} and Liu, {Chun Jen} and Teerha Piratvisuth and Lok, {Anna S.F.} and Lim, {Seng Gee}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12072-014-9549-1",
language = "English",
volume = "8",
pages = "382--394",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

Dan, YY, Wong, JB, Hamid, SS, Han, K, Jia, JD, Liu, CJ, Piratvisuth, T, Lok, ASF & Lim, SG 2014, 'Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries', Hepatology International, vol. 8, no. 3, pp. 382-394. https://doi.org/10.1007/s12072-014-9549-1

Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. / Dan, Yock Young; Wong, John B.; Hamid, Saeed S.; Han, KwangHyub; Jia, Ji Dong; Liu, Chun Jen; Piratvisuth, Teerha; Lok, Anna S.F.; Lim, Seng Gee.

In: Hepatology International, Vol. 8, No. 3, 01.01.2014, p. 382-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries

AU - Dan, Yock Young

AU - Wong, John B.

AU - Hamid, Saeed S.

AU - Han, KwangHyub

AU - Jia, Ji Dong

AU - Liu, Chun Jen

AU - Piratvisuth, Teerha

AU - Lok, Anna S.F.

AU - Lim, Seng Gee

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. Methods: The working party consisted of expert hepatologists, virologists and epidemiologists from 11 representative countries in the Asia Pacific region. Meetings were conducted at the 20th APASL Annual Meeting in 2010 to determine consensus estimates for modeling and at the 21st and 22nd APASL meetings in 2011 and 2012, respectively to review and approve the models. Results: The consensus cost-effectiveness model used Singapore as base case analysis and was validated using actual data from the Singapore Cancer, Diseases and Death Registries. Simulation for Singapore, China, Thailand, Pakistan, Taiwan and Korea were performed. Antivirals with high resistance barriers like entecavir and tenofovir had the highest retail cost but were the most cost-effective therapy in developed countries such as Singapore, Taiwan and Korea while generic tenofovir was most cost effective in Thailand and Pakistan. The cost effectiveness of different treatment strategies varied significantly between countries and was affected by medication cost, economic affordability, access to liver transplantation and the prevailing health of the general population. Conclusion: Choosing treatment strategies for hepatitis B based on low retail drug cost can be misleading because more expensive drugs may be more cost effective when considering long-term health outcomes and costs. Cost-effectiveness data should be individualized to countries based on their unique socio-economic conditions. Governmental policies which subsidize more costly drugs that have lower risk of drug resistance can benefit more patients.

AB - Purpose: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. Methods: The working party consisted of expert hepatologists, virologists and epidemiologists from 11 representative countries in the Asia Pacific region. Meetings were conducted at the 20th APASL Annual Meeting in 2010 to determine consensus estimates for modeling and at the 21st and 22nd APASL meetings in 2011 and 2012, respectively to review and approve the models. Results: The consensus cost-effectiveness model used Singapore as base case analysis and was validated using actual data from the Singapore Cancer, Diseases and Death Registries. Simulation for Singapore, China, Thailand, Pakistan, Taiwan and Korea were performed. Antivirals with high resistance barriers like entecavir and tenofovir had the highest retail cost but were the most cost-effective therapy in developed countries such as Singapore, Taiwan and Korea while generic tenofovir was most cost effective in Thailand and Pakistan. The cost effectiveness of different treatment strategies varied significantly between countries and was affected by medication cost, economic affordability, access to liver transplantation and the prevailing health of the general population. Conclusion: Choosing treatment strategies for hepatitis B based on low retail drug cost can be misleading because more expensive drugs may be more cost effective when considering long-term health outcomes and costs. Cost-effectiveness data should be individualized to countries based on their unique socio-economic conditions. Governmental policies which subsidize more costly drugs that have lower risk of drug resistance can benefit more patients.

UR - http://www.scopus.com/inward/record.url?scp=84905570338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905570338&partnerID=8YFLogxK

U2 - 10.1007/s12072-014-9549-1

DO - 10.1007/s12072-014-9549-1

M3 - Article

AN - SCOPUS:84905570338

VL - 8

SP - 382

EP - 394

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -